Opinion|Videos|June 12, 2024
Optimizing Benefit Design and Implementation for Improved PDT Access
Panelists explore how payers choose between pharmacy and medical benefit designs for covering prescription digital therapeutics (PDTs), optimizing patient access and adoption, and discussing why the selected pathway was considered optimal for a specific PDT.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How do payers determine the optimal pharmacy vs. medical benefit design to cover prescription digital therapeutics (PDTs) to enhance patient access and adoption?
- What factors and considerations went into the decision to cover a particular PDT through the pharmacy benefit versus the medical benefit, and why was that pathway determined to be optimal for that specific PDT?
- What characteristics and factors did Mass Health consider when selecting clinics to prescribe and implement the use of prescription digital therapeutics?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Results from the phase 3 DeLLphi-305 trial, presented at ESMO 2026 and published in the New England Journal of Medicine, showed median overall survival of 21.1 months with the combination vs 12.7 months with durvalumab alone.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.
The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.
Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5